hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06302413 id: 1805574553; Aims 9-10 id: 1R01AA029396-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01AA029396-01 briefTitle: Enhancing Prospective Thinking in Early Recovery acronym: HOME overallStatus: RECRUITING date: 2024-02-15 date: 2027-07-31 date: 2027-07-31 date: 2024-03-08 date: 2024-03-08 name: Indiana University class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering alcohol use disorder (AUD) persons. The main question\[s\] this trial aims to answer are:
Will the Virtual Reality (VR) intervention decrease the number of stimulant use days? Will the VR intervention produce longer abstinence periods during follow-up visits? Will the VR intervention increase alcohol abstinence rates? Will the VR intervention increase future self-identification? Will the VR intervention increase self-reported future time perspective? Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day? Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups? Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: All study participants are randomly assigned to a group prior to study enrollment. Participants will not be made aware of their group assignment. whoMasked: PARTICIPANT count: 500 type: ESTIMATED name: Virtual Reality name: Virtual Reality measure: Reduced Use of Drug Using Days measure: Increased Length of Abstinence measure: Increased (overall) Abstinence measure: Future Self-identification with Future Self Continuity Questionnaire measure: Future Time Perspective with the Delayed Discounting Behavioral Task and Future Self Continuity Questionnaire measure: Delayed Reward Preference with the Delayed Discounting Behavioral Task sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Indiana University School of Medicine - Goodman Hal status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States name: Sarah Turo, BA role: CONTACT phone: 317-963-7220 email: sturo@iu.edu name: Brandon G Oberlin, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 hasResults: False
nctId: NCT06302400 id: RS-IC04 briefTitle: Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma acronym: RHEPaiR overallStatus: RECRUITING date: 2024-02-22 date: 2027-02 date: 2027-02 date: 2024-03-08 date: 2024-03-08 name: Imperial College London class: OTHER name: Terumo Europe N.V. briefSummary: The goal of this clinical trial is to test the safety and effectiveness of a medical device called 166-Holmium microspheres (QuiremSpheres®) in patients with hepatocellular carcinoma (HCC) . The main questions it aims to answer are:
Before receiving treatment with QuiremSpheres® the participant will receive a 'scout' dose of the microspheres, to check whether there is distribution of the radioactivity to other non-target areas of the body. This is measured using Single-Photon Emission Computed Tomography-CT imaging. If the distribution to non-target areas is deemed to not be too high, the participant will go on to receive the individualised therapeutic dose of QuiremSpheres®. Follow-up visits will occur 3 and 6 weeks post-treatment dose, and then at 3 and 6 months. conditions: Carcinoma, Hepatocellular studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: 166Holmium microspheres (QuiremSpheres®) measure: The incidence of adverse and serious adverse events in patients receiving individualized treatment with 166Ho- microspheres, using National Cancer Institute CTCAE v5.0. measure: The rate of efficacy as defined as overall response rate (ORR) in patients receiving individualized treatment with 166Ho- microspheres, using modified RECIST (mRECIST) response evaluation criteria. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Imperial College Healthcare NHS Trust status: RECRUITING city: London zip: W12 0HS country: United Kingdom name: Rohini Sharma, Professor role: CONTACT phone: 02033133720 email: r.sharma@imperial.ac.uk lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06302387 id: BEC-LSMU(R)-27 briefTitle: Acellular Dermal Matrix Versus Tenting Technique in Peri-implant Soft Tissue Augmentation and Crestal Bone Stability overallStatus: COMPLETED date: 2018-01-01 date: 2020-04-01 date: 2023-02-01 date: 2024-03-08 date: 2024-03-08 name: Harvard Medical School (HMS and HSDM) class: OTHER briefSummary: This study looks at two ways to make gums thicker and bones stable around dental implants for people with thin gums. It compares two methods in 40 people: one method uses a special graft, and the other uses a technique called tenting. The goal is to see which method might work better for making the gums and bones around implants healthier. The check-ups are planned when the implant is put in and again after one year. The study focuses on how these methods are done without talking about what the results are. conditions: Soft Tissue Augmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The interventional study model for this trial is a two-arm, double-blind, randomized, prospective controlled clinical trial. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: double-blind, where neither the patients nor the clinicians responsible for treatment know the specific treatment modality whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 40 type: ACTUAL name: Acellular Dermal Matrix name: Soft Tissue Expansion using Tenting Technique measure: Crestal Bone Levels measure: Vertical soft tissue thickness measure: PPD measure: BOP measure: PI sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VIC Clinic city: Vilnius zip: 01362 country: Lithuania lat: 54.68916 lon: 25.2798 hasResults: False
nctId: NCT06302374 id: GR2001-001 briefTitle: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults overallStatus: COMPLETED date: 2023-03-04 date: 2023-11-01 date: 2024-02-19 date: 2024-03-08 date: 2024-03-08 name: Genrix (Shanghai) Biopharmaceutical Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and Immunogenicity characteristics of GR2001 and compare the anti-tetanus neutralizing antibody titers of GR2001 with human tetanus immunoglobulin (HTIG)in healthy adult subjects. conditions: Tetanus studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In the phase I part of the study, a total of 94 healthy subjects will be enrolled. The 94 healthy adult subjects will be enrolled into 7 cohorts sequentially. Each participant will receive a single IM dose of GR2001 or placebo or HTIG according to the cohort in which they were enrolled. After injection (Day 0), participants will remain in the study site for observation up to Day 1. The phase I part will last for 105 days following the assessments of safety, PK, PD and ADA.
In the phase II part of the study, a total of 108 healthy subjects will be enrolled. The 108 healthy subjects will be randomly assigned to the experimental group and the control group based on a ratio of 1:1:1:2:2:2.The phase II part will last for 105 days following the assessments of safety, PK, PD and ADA. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double Blind whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 202 type: ACTUAL name: GR2001 name: Placebo name: HTIG name: Tetanus Toxoid measure: Incidence of AEs(Phase I) measure: Tetanus-antibody titer(Phase II) measure: Tetanus-antibody titer(Phase I/II) measure: Incidence of ADA(Phase I/II) measure: Incidence of AEs(Phase II) measure: Peak plasma concentration(Cmax) measure: Area under the plasma concentration versus time curve (AUC) measure: Time of maximum plasma concentration (Tmax) measure: Terminal half-life (T1/2) measure: Apparent total body clearance (CL/F) measure: Apparent volume of distribution (Vd/F) measure: The elimination rate constant (Kel) measure: Mean Residence Time (MRT) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Huashan Hospital affiliated of Fudan University city: Shanghai state: Shanghai zip: 200040 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06302361 id: 23/54225 briefTitle: Lymphovenous Anastomosis for Breast Cancer Lymphedema overallStatus: RECRUITING date: 2024-03-01 date: 2026-06-30 date: 2026-06-30 date: 2024-03-08 date: 2024-03-08 name: Odense University Hospital class: OTHER name: Vejle Hospital name: Zealand University Hospital name: Herlev and Gentofte Hospital briefSummary: This multi-center cohort study focuses on evaluating the efficacy of lymphovenous anastomosis (LVA) for treating pitting lymphedema in female breast cancer survivors. Conducted across multiple centers in Denmark, including Odense University Hospital, Herlev Hospital, Lillebaelt Hospital Vejle, and Zealand University Hospital, it aims to assess LVA's impact on reducing arm volume and improving quality of life in patients with upper extremity lymphedema secondary to breast cancer treatment.
The study adheres to ethical guidelines, ensuring patient safety and the integrity of the research. conditions: Lymphedema conditions: Lymphedema Arm conditions: Breast Cancer Lymphedema conditions: Lymphedema, Secondary conditions: Lymphedema; Surgical conditions: Lymphedema of Upper Limb conditions: Lymphedema, Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Multi-center cohort study primaryPurpose: TREATMENT masking: NONE count: 47 type: ESTIMATED name: Lymphovenous anastomosis (LVA) measure: Arm volume (Water Displacement) measure: Arm volume (Arm Circumferences) measure: Health-related quality of life (LYMPH-Q) measure: General quality of life (SF-36) measure: Arm and shoulder function (DASH) measure: L-Dex measure: LVA patency measure: Skin Fibrosis measure: Surgery duration measure: Body composition sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Plastic Surgery, Odense University Hospital status: RECRUITING city: Odense state: Region Of Southern Denmark zip: 5000 country: Denmark name: Caroline Lilja, MD role: CONTACT phone: +4560555340 email: caroline.lilja@rsyd.dk lat: 55.39594 lon: 10.38831 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-02-07 uploadDate: 2024-03-04T05:57 filename: Prot_SAP_000.pdf size: 934504 hasResults: False
nctId: NCT06302348 id: PTC923-PKU-401 briefTitle: A Study of Sepiapterin in Participants With Phenylketonuria (PKU) acronym: EPIPHENY overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2031-02-28 date: 2031-02-28 date: 2024-03-08 date: 2024-03-08 name: PTC Therapeutics class: INDUSTRY briefSummary: The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood. conditions: Phenylketonuria studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: Sepiapterin measure: Mean Change From Baseline in Full-scale Intelligence Quotient (FSIQ) Weschler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV) Score measure: Mean Change From Baseline in FSIQ Weschler Intelligence Scale for Children - Fifth Edition (WISC-V) Score measure: Change From Baseline in Phenylketonuria-Quality of Life (PKU-QOL) Questionnaire Score measure: Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Score measure: Mean Change From Baseline in FSIQ (WPPSI-IV) Score measure: Mean Change From Baseline in FSIQ (WISC-V) Score measure: Change From Baseline in Mean Blood Phe Levels sex: ALL maximumAge: 12 Years stdAges: CHILD facility: Indiana University city: Indianapolis state: Indiana zip: 46202 country: United States name: Susan Romie role: CONTACT name: Melissa Lah role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 hasResults: False
nctId: NCT06302335 id: 2022-0442 briefTitle: Povidone-iodine vs Saline Solution in Colorectal Surgeries and Its Effects on the Surgical Site Infection overallStatus: RECRUITING date: 2023-01-02 date: 2027-12-31 date: 2027-12-31 date: 2024-03-08 date: 2024-03-08 name: Hospital de Clinicas de Porto Alegre class: OTHER briefSummary: Considering the relatively high incidence of surgical site infection (SSI) in colorectal surgery, this trial will compare rates of SSI in patients undergoing colorectal resections followed by surgical wound irrigation with povidone-iodine versus the group of patients undergoing surgical wound irrigation with saline solution. The trial will be conducted in a large university hospital in Southern Brazil. conditions: Surgical Site Infection studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This a randomized clinical trial involving patients undergoing colorectal surgeries who will submitted to the application of povidone-iodine versus saline solution in their surgical sites. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants will not know what kind of substance will be used during the surgery. whoMasked: PARTICIPANT count: 228 type: ESTIMATED name: Povidone-iodine name: Saline solution measure: Surgical site infection measure: Intracavitary surgical infection sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital de Clinicas de Porto Alegre status: RECRUITING city: Porto Alegre state: RS zip: 90.035-903 country: Brazil name: Daniel C Damin role: CONTACT phone: +5551996020442 email: damin@terra.com.br lat: -30.03306 lon: -51.23 hasResults: False
nctId: NCT06302322 id: 158200-07-512-149 briefTitle: Long-term Follow up of Mucosal Tissue Height Influence on Peri-implant Bone Levels. overallStatus: COMPLETED date: 2021-01-07 date: 2022-08-15 date: 2022-10-01 date: 2024-03-08 date: 2024-03-08 name: Harvard Medical School (HMS and HSDM) class: OTHER briefSummary: Our study looks into how the thickness of the gum tissue affects the health of the bone around dental implants over ten years. We include 59 people and divide them into three groups based on their gum tissue thickness. Some have naturally thin gums, some have thin gums that were made thicker with a special procedure, and some already had thick gums. We try to find out if having thicker gums, whether naturally or through enhancement, can help keep the bone around dental implants healthy in the long run. conditions: Edentulous Alveolar Ridge studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 59 type: ACTUAL name: Thin Tissues name: Thick Tissues name: Surgically augmented thin tissues measure: Crestal Bone Levels measure: PPD measure: BOP measure: PI sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VIC Clinic city: Vilnius zip: 01362 country: Lithuania lat: 54.68916 lon: 25.2798 hasResults: False
nctId: NCT06302309 id: NL85217.091.23 briefTitle: Tackling Anxiety-related Freezing of Gait in People With Parkinson's Disease acronym: TACKLING-FOG overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-09 date: 2025-09 date: 2024-03-08 date: 2024-03-08 name: Radboud University Medical Center class: OTHER briefSummary: The purpose of this study is to investigate whether personalized strategies that target anxiety and stress surrounding freezing of gait can alleviate freezing of gait in people with Parkinson's Disease. conditions: Freezing of Gait studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE maskingDescription: Randomization will be performed in CastorEDC, a web-based data management system for academic studies (www.castoredc.com). Breaking of the randomization code is not applicable, since researchers and trainers cannot be blinded. count: 40 type: ESTIMATED name: Psychological intervention measure: % time frozen during a personalized gait trajectory measure: subjective impact of anxiety and stress on FOG, as measured with a Visual Analogue Scale measure: Heart Rate Variability measure: The Parkinson Anxiety Scale (PAS) measure: Gait-Specific Attention Profile measure: he Updated Perceived Control over Falling Scale (UP-COF) measure: New Freezing of Gait Questionnaire measure: The Parkinson's Disease Questionnaire measure: The Rosenberg self-esteem score measure: Perceived Stress Scale measure: Montreal Cognitive Assessment measure: Unified Parkinson's Disease Rating Scale Part III sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06302296 id: Hama University/ briefTitle: Evaluating the Effect of Injectable Platelet-rich Fibrin on Accelerating Orthodontic Tooth Movement overallStatus: RECRUITING date: 2024-04-20 date: 2024-05-15 date: 2025-07-15 date: 2024-03-08 date: 2024-03-08 name: Hama University class: OTHER briefSummary: One of the main goals of orthodontic treatment is the reduction of treatment time through faster tooth movement. The previous studies evaluating platelet-rich fibrin (PRF) and orthodontic tooth movement (OTM) are limited, which makes the results difficult to generalize. conditions: Tooth Mobility conditions: Injectable Platelet-rich Fibrin studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 14 type: ESTIMATED name: injectable form of PRF name: Placebo injection measure: Leveling and alignment maxillary incisors sex: ALL minimumAge: 18 Years maximumAge: 26 Years stdAges: ADULT facility: Fadi Jnaid status: RECRUITING city: Hama country: Syrian Arab Republic name: Fadi Jnaid, Associate Professor role: CONTACT email: Drfadijnaid@gmail.com name: PhD role: CONTACT phone: 0988499015 lat: 35.13179 lon: 36.75783 hasResults: False
nctId: NCT06302283 id: 114/23-EP briefTitle: Collateral Effects of Pandemics - Care for Informal Caregivers acronym: COLLPAN-3A overallStatus: ENROLLING_BY_INVITATION date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-08 date: 2024-03-08 name: University of Bonn class: OTHER name: Wuerzburg University Hospital name: Johannes Gutenberg University Mainz name: Universitätsklinikum Hamburg-Eppendorf briefSummary: The study is a workpackage in the German research consortium COLLPAN. The study will map collateral effects in terms of psychosocial and spiritual burden of informal caregivers during after the pandemic and identification/mapping of risk factors.It will also map available therapeutic and preventive interventions and relief of this burden for the present situation and for future pandemics. conditions: Bereavement studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: Survey measure: Bereavement burden measure: Anxiety measure: Depression measure: Caregiving burden sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Bonn city: Bonn zip: 53127 country: Germany lat: 50.73438 lon: 7.09549 hasResults: False
nctId: NCT06302270 id: K2024-0507 briefTitle: CFTR Modulators in Pregnancy and Postpartum overallStatus: RECRUITING date: 2024-03-15 date: 2034-01-31 date: 2039-01-31 date: 2024-03-08 date: 2024-03-08 name: Region Stockholm class: OTHER_GOV name: Karolinska Institutet briefSummary: Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk. conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 75 type: ESTIMATED measure: Health effects in the newborn infant sex: ALL maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Stockholm CF center status: RECRUITING city: Stockholm country: Sweden name: Terezia Pinzikova, MD, PhD role: CONTACT phone: +46 8 123 80000 email: jenny.svedenkrans@regionstockholm.se lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06302244 id: R-21075263 briefTitle: Multimodal Neuromonitoring in Acute Brain Injury overallStatus: ACTIVE_NOT_RECRUITING date: 2017-03-27 date: 2023-06-01 date: 2024-11-01 date: 2024-03-08 date: 2024-03-12 name: Rigshospitalet, Denmark class: OTHER briefSummary: Acute brain injury due to aneurysmal subarachnoid haemorrhage (SAH) or traumatic brain injury (TBI) is a condition with a high mortality, and surviving patients often have permanent disabilities. Multimodal neuromonitoring of intracranial pressure, brain tissue oxygen tension (PbtO2), and brain energy metabolism (measured with microdialysis (MD)) may help individualise the treatment of this patient group to protect the brain and potentially improve outcomes. However, there is still a significant lack of knowledge regarding the advantages and disadvantages of this type of monitoring.
The individual studies are detailed below: conditions: Acute Brain Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 200 type: ACTUAL measure: Correlation between systemic glucose and microdialysis glucose measure: Median goodness of fit (Pearsons R2) of the relationship between PaO2 (kPa) and PbtO2 (mmHg). measure: Correlation between systemic lactate and microdialysis lactate when corrected for PbtO2 and cerebral perfusion pressure. measure: The predictive value of glutamate measured by intracerebral microdialysis for episodes of neuroworsening measure: The predictive value of glutamate measured by intracerebral microdialysis for 6-month functional outcome measure: Length of hospital stay measure: Mixed effects linear regression of the relationship betwen PaO2 (kPa) and PbtO2 (mmHg). measure: Functional outcome at six months measure: Mortality at six months measure: Length of stay in the ICU sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rigshospitalet city: Copenhagen zip: 2100 country: Denmark lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06302231 id: 16690919.5.0000.5347 briefTitle: Effects of Time-restricted Eating and Aerobic Exercise Training in Women With Overweight and Obesity overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-08 date: 2024-03-08 name: Federal University of Rio Grande do Sul class: OTHER briefSummary: Time-restricted eating (TRE) is a dietary approach that aims to increase fasting time and decrease the eating window. Promising TRE effects on weight loss and improvements in some cardiometabolic risk factors have been reported in studies in animals and humans. However, the impacts of TRE combined with aerobic exercise training in individuals with overweight and obesity have been insufficiently investigated.